RPTO/SB/21 (08-00)

IPE			Applic	ation Number	10/729,795
o transmittal			Filing	Date	December 5, 2003
APR 0 5 2007 By) FORM		First N	lamed Inventor	Walters	
to be used for By cor	rrespondence after ini	tial filing)	Group	Art Unit	1644
* PARENTAL PROPERTY OF THE PARENTAL PROPERTY O			Exami	ner Name	Skelding, Z. S.
Total Number of Pages in This Submission 7			Attorne	ey Docket Number	011823-012510US
		ENCL	SURES	(check all that apply)	
Fee Transmittal F	Form (orig. + 1 cc.)		ment Pap Application		After Allowance Communication to Group
Fee Attached		Drawin	g(s)		Appeal Communication to Board of Appeals and Interferences
Amendment / Res	sponse	_	•	d Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final		and Ac	company	Slip (PTO/SB/69) ing Petition	Proprietary Information
		n to Convert to a conal Application		Status Letter	
		of Attorney, Revocation e of Correspondence Address		Other Enclosure(s) (please identify below):	
¬		Termin	nal Disclaimer		1) Return receipt postcard
_ Express Abandon	nment Request	Reque	est for Refund		2) Two (2) references 3) Supplementary European Search
Information Disclo	osure Statement	CD, Nu	umber of CD(s)		Report
Certified Copy of Document(s)	Priority	Rema	rks	Deposit Account 20-	s authorized to charge any additional fee's to 1430. ges <u>does no</u> t include cited references.
Response to Miss		<u></u>		Total number of pa	ges <u>ades no</u> t molade ened relevances.
Response to Parts under 3	Missing				
_	SIGNAT	URE OF	APPLIC	ANT, ATTORNEY, O	OR AGENT
Firm	Townsend and Tow	nsend and	Crew LLF		
and Individual name Joe Liebeschuetz				Reg N	o. 37,505
Signature Hulushi					
Date	April 2, 2007				
		CE	RTIFICA	TE OF MAILING	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date

April 2, 2007

61020397

Signature

Effective on 12/08/2004 Per pursion to the Consolidated Appropriation	4.		Complete	if Known			
		Application Number	10/729,7	95			
FEE KANSI	MITTAL	Filing Date	Decembe	er 5, 2003			
APR 0 5 2007 "For FY 200)5 [First Named Inventor	Walters				
Applicant classes small entity status. S		Examiner Name	Skelding	, Z. S.			
Applicant cargins small entity status. So	ee 3/ OFN 1.2/	Art Unit	1644				
TOTAL AMOUNT OF PAYMENT (\$) 1	180.00	Attorney Docket No.	011823-0	012510US			
METHOD OF PAYMENT (check all th	nat apply)						
Check Credit Card Mo	oney Order None	Other (please ide	ntify):				
Deposit Account Deposit Account	Number: 20-1430	Deposit Account Nam	ne: Townsen	d and Townsen	d and Crew LLP		
For the above-identified deposit a	account, the Director is he	ereby authorized to: (che	ck all that a	pply)			
Charge fee(s) indicated belo	ow	Charge fee(s	s) indicated	below, except f	or the filing fee		
Charge any additional fee(s) under 37 CFR 1.16 and 1.17 WARNING: Information on this form may become of the companion of the	7	Credit any or			redit card		
FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EX		DOLLETEC TY	. A B AIN! A T ! C	ON EEEO			
•	FEES SEA	RCH FEES EX Small Entity	AMINATIC <u>Small I</u>	<u>Entity</u>			
Application Type Fee (\$) Fe			ee (\$) Fee	(\$)	Fees Paid (\$)		
Utility 300	150 500	250	200 100	0 _			
Design 200	100 100	50	130 6	5			
Plant 200	100 300	150	160 80	0 _			
Reissue 300	150 500	250	600 300	0 _			
Provisional 200	100 0	0	0	0 _			
2. EXCESS CLAIM FEES Fee Description Each claim over 20 or, for Reissues, 6 Each independent claim over 3 or, for Multiple dependent claims Total Claims Extra Claims -20 or HP =	r Reissues, each indep <u>s </u>	endent claim more th	an in the o		360 180		
HP = highest number of total claims paid for, if gr Indep. Claims Extra Claims		e Paid (\$)			_		
-3 or HP =		\$0	•				
HP = highest number of independent claims paid	for, if greater than 3						
3. APPLICATION SIZE FEE If the specification and drawings exc for each additional 50 sheets or f Total Sheets - 100 =	fraction thereof. See 3 Number of each	35 U.S.C. 41(a)(1)(G) ach additional 50 or fra	and 37 Cl	FR 1.16(s). of <u>Fee (\$)</u>	for small entity) Fee Paid (\$) =		
4. OTHER FEE(S)	4. OTHER FEE(S) Fees Paid (\$)						
Non-English Specification, \$130 fee (no small entity discount)							
Other: Information Disclosure Statement (after office action) 180.00							
SUBMITTED BY							
Signature Juliu		Registration No. (Attorney/Agent) 37,50	05	Telephone	(650) 326-2400		
Name (Print/Type) Joe Liebeschuetz				Date April 2	2, 2007		

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 011823-012510US Client Reference No.: 1065.20US

Mail Stop Amendment
Commissioner for Patents

P.O. Box 1450 Akasandria, VA 22313-1450

4/2/07

On **%** APR **0** 5 2007

WAYSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ian Walters

Application No.: 10/729,795

Filed: December 5, 2003

For: METHODS OF TREATMENT OF ULCERATIVE COLITIS WITH ANTI-

CD3 ANTIBODIES

Confirmation No.: 2275

Examiner: Zachary S. Skelding

Art Unit: 1644

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER

37 CFR §1.97 and §1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed.

Also enclosed is a copy of the Supplementary European Search Report for the corresponding European application.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

04/05/2007 NNGUYEN1 00000126 201430 10729795 01 FC:1806 180.00 DA

PATENT

Ian Walters

Application No.: 10/729,795

Page 2

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Joe Liebeschuetz Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

JOL:crf

60990792



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	(000 10) 0		
Sheet	1	of	2

Complete if Known						
Application Number	10/729,795					
Filing Date	December 5, 2003					
First Named Inventor	Walters					
Art Unit	1644					
Examiner Name	Zachary S. Skelding					
Attorney Docket Number	011823-012510US					

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number Kind Odde					
. 	·····						
				-			

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Fo	reign Patent D	ocument	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages		
mmais		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T ⁶	
	ļ		·····	***************************************				ļ	
					·····	***************************************			
	[***************************************				\$ 144 144 144 144 144 144 144 144 144 14		
	<u> </u>				······································	***************************************			
		<u> </u>				<u> </u>	L	Щ_	

Examiner	•	Date	
Signature		Considered	
- · · · · · · · · · · · · · · · · · · ·			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. 600007022

Substitute for	or form 1449B/PTO			Complete if Known		
				Application Number	10/729,795	
INFO	RMATION DIS	CLOS	URE	Filing Date	December 5, 2003	
STAT	STATEMENT BY APPLICANT			First Named Inventor	Walters	
				Art Unit	1644	
('Use as many sheets as r	ecessary)		Examiner Name	Zachary S. Skelding	
Sheet	2	of	2	Attorney Docket Number	011823-012510US	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	AA	CARPENTER et al., "A humanized non-FcR-binding antiCD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease," <u>Blood</u> , 99(8):2712-2719 (2002).					
	AB	HEAD et al., "Inflamatory Bowel Disease Part I: Ulcerative Colitis Pathophysiology and Conventional and Alternative Treatment Options," <u>Alternative Medicine Review</u> , 8(3):247-283 (2003).					
	AC	TUVLIN et al., "Novel therapies in the treatment of ulcerative colitis," <u>Expert Opin. Investig. Drugs</u> , 12(3):483-490 (2003).					
		y					
	•						

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.